Maze Therapeutics finance SVP to resign June 1
Maze Therapeutics, Inc. reported that Amy Bachrodt, its Senior Vice President of Finance, has given notice that she will resign effective June 1, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Maze Therapeutics, Inc. reported that Amy Bachrodt, its Senior Vice President of Finance, has given notice that she will resign effective June 1, 2026. The company states her resignation is not due to any disagreement regarding operations, policies, practices, or financial reporting. Following her departure, Chief Financial Officer Misbah Tahir will also serve as the company’s principal accounting officer, consolidating financial leadership under the CFO role.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Terms
Emerging growth company, principal accounting officer, Item 5.02, Nasdaq Stock Market LLC
4 terms
Emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
principal accounting officer financial
"Misbah Tahir, the Company’s Chief Financial Officer, will be designated principal accounting officer"
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
Item 5.02 regulatory
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors"
Item 5.02 is a specific disclosure category on the U.S. Securities and Exchange Commission’s Form 8‑K that requires public companies to report changes in key personnel and related compensation arrangements. It covers departures and appointments of directors and certain officers, elections of directors, and new or material changes to compensatory agreements for those persons; the company must file a Form 8‑K with the required information and any related exhibits within the SEC’s prescribed reporting timeframe. The item is a rule‑based reporting obligation under U.S. securities law, so its scope and timing follow the SEC’s definitions and deadlines rather than informal usage.
Nasdaq Stock Market LLC market
"MAZE | | The Nasdaq Stock Market LLC"
Nasdaq Stock Market LLC is the company that operates the Nasdaq electronic stock exchange, a large centralized marketplace where shares of publicly traded companies are listed and bought and sold. Think of it as a high-speed digital auction house and storefront combined: being listed there gives a company visibility and easier access to many buyers, while investors benefit from transparent prices, fast trades and regulated rules that help protect fair trading.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What leadership change did Maze Therapeutics (MAZE) disclose in this 8-K?
Maze Therapeutics disclosed that Senior Vice President of Finance, Amy Bachrodt, will resign effective June 1, 2026. The company also stated that its Chief Financial Officer, Misbah Tahir, will assume the role of principal accounting officer after her departure.
When will Maze Therapeutics’ Senior Vice President of Finance resign?
Amy Bachrodt’s resignation as Senior Vice President of Finance will be effective June 1, 2026. She provided notice on May 18, 2026, allowing a short transition period before Chief Financial Officer Misbah Tahir assumes principal accounting officer responsibilities.
Who will serve as principal accounting officer at Maze Therapeutics after June 1, 2026?
After June 1, 2026, Maze Therapeutics’ Chief Financial Officer, Misbah Tahir, will be designated as the company’s principal accounting officer. This change places both overall financial leadership and formal accounting responsibilities under the CFO function at the company.
What SEC item does this Maze Therapeutics (MAZE) 8-K relate to?
This Maze Therapeutics 8-K relates to Item 5.02, which covers departures and appointments of directors or certain officers and compensatory arrangements. The filing specifically addresses the resignation of the Senior Vice President of Finance and the reassignment of principal accounting officer duties.
AI-generated analysis. How Rhea-AI works. Not financial advice.
